drugset
drugset / Trial / NCT02346175

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients

NCT02346175 ↗

Phase 1 Completed 30 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single and multiple oral doses of 5mg to 20 mg SHR3824 in Type 2 diabetes mellitus patients.

Timeline

Start
2014-06
Primary completion
2014-09
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Henagliflozin Small molecule 5 mg Oral
Subject Henagliflozin Small molecule 10 mg Oral
Subject Henagliflozin Small molecule 20 mg Oral

Indications

type 2 diabetes mellitus